Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AxV-128/Tc Imaging in COPD
NCT02978144Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Jun 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium-tc99m-labeled annexin a5 in chronic obstructive pulmonary disease (COPD), sponsored by Columbia University. Primary endpoint: Mean AxV-128/Tc Uptake at 18 months. Started Jun 2017; status: terminated.
02
Drugs
technetium-tc99m-labeled annexin a5
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02978144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978144.